| The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant HR+/HER2− metastatic breast cancer: biological mechanisms and new treatments D Presti, E Quaquarini Cancers 11 (9), 1242, 2019 | 92 | 2019 |
| Impact of COVID-19 outbreak on cancer patient care and treatment: data from an outpatient oncology clinic in Lombardy (Italy) E Quaquarini, G Saltalamacchia, D Presti, G Caldana, V Tibollo, ... Cancers 12 (10), 2941, 2020 | 44 | 2020 |
| T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study B Conte, A Fabi, F Poggio, E Blondeaux, C Dellepiane, A D’Alonzo, ... Clinical Breast Cancer 20 (2), e181-e187, 2020 | 39 | 2020 |
| Development and validation of a predictive model of severe fatigue after breast cancer diagnosis: toward a personalized framework in survivorship care A Di Meglio, J Havas, D Soldato, D Presti, E Martin, B Pistilli, G Menvielle, ... Journal of Clinical Oncology 40 (10), 1111-1123, 2022 | 32 | 2022 |
| Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: a systematic review D Presti, FG Dall’Olio, B Besse, JM Ribeiro, A Di Meglio, D Soldato Critical Reviews in Oncology/Hematology 177, 103773, 2022 | 27 | 2022 |
| Long-term longitudinal patterns of patient-reported fatigue after breast cancer: a group-based trajectory analysis I Vaz-Luis, A Di Meglio, J Havas, M El-Mouhebb, P Lapidari, D Presti, ... Journal of Clinical Oncology 40 (19), 2148-2162, 2022 | 25 | 2022 |
| Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy A Di Meglio, D Soldato, D Presti, I Vaz-Luis Current Opinion in Oncology 33 (6), 553-573, 2021 | 17 | 2021 |
| Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre … R Palumbo, R Torrisi, F Sottotetti, D Presti, A Rita Gambaro, E Collovà, ... Therapeutic Advances in Medical Oncology 13, 1758835920987651, 2021 | 16 | 2021 |
| Role of androgen receptor expression in early stage ER+/PgR−/HER2–breast cancer B Tagliaferri, E Quaquarini, R Palumbo, E Balletti, D Presti, A Malovini, ... Therapeutic Advances in Medical Oncology 12, 1758835920958355, 2020 | 15 | 2020 |
| The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional … L Provenzano, R Lobefaro, F Ligorio, E Zattarin, L Zambelli, C Sposetti, ... Therapeutic Advances in Medical Oncology 15, 17588359231165978, 2023 | 10 | 2023 |
| Gruppo Italiano Mammella (GIM) Study Group. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab … B Conte, A Fabi, F Poggio, E Blondeaux, C Dellepiane, A D’Alonzo, ... Clin Breast Cancer 20 (2), e181-7, 2020 | 9 | 2020 |
| Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors E Zattarin, D Presti, L Mariani, C Sposetti, R Leporati, A Menichetti, C Corti, ... NPJ breast cancer 9 (1), 27, 2023 | 8 | 2023 |
| Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: a monocentric, retrospective … R Lobefaro, L Mariani, G Peverelli, F Ligorio, G Fucà, A Rametta, ... Clinical Breast Cancer 23 (3), e151-e162, 2023 | 4 | 2023 |
| Factors associated with enrolment in clinical trials among women with early-stage breast cancer D Presti, J Havas, D Soldato, P Lapidari, E Martin, B Pistilli, C Jouannaud, ... ESMO open 7 (3), 100513, 2022 | 3 | 2022 |
| Abstract P4-11-34: an integrated clinical, behavioral and biological model to predict the risk of weight gain among breast cancer survivors (BCS) D Soldato, AD Meglio, C Pradon, AD Noce, D Presti, J Havas, ... Cancer Research 82 (4_Supplement), P4-11-34-P4-11-34, 2022 | 3 | 2022 |
| Abstract HER2-02: HER2-02 HER2-low status is associated with worse clinical outcomes in hormone receptor-positive, HER2-negative advanced breast cancer patients treated with … E Zattarin, C Sposetti, R Leporati, L Mariani, A Menichetti, C Corti, ... Cancer Research 83 (5_Supplement), HER2-02-HER2-02, 2023 | 2 | 2023 |
| Coffee and tea consumption, patient‐reported, and clinical outcomes in a longitudinal study of patients with breast cancer D Soldato, J Havas, TE Crane, D Presti, P Lapidari, N Rassy, B Pistilli, ... Cancer 128 (19), 3552-3563, 2022 | 2 | 2022 |
| Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors E Zattarin, L Mariani, A Menichetti, R Leporati, L Provenzano, F Ligorio, ... Therapeutic Advances in Medical Oncology 15, 17588359231204857, 2023 | 1 | 2023 |
| Abstract P3-12-12: ATTITUDE: Understanding and reducing ATTrition in longiTUDinal studiEs of cancer survivors P Lapidari, J Havas, D Presti, D Soldato, E Martin, B Pistilli, A Bertaut, ... Cancer Research 82 (4_Supplement), P3-12-12-P3-12-12, 2022 | 1 | 2022 |
| 1694P Coffee and tea consumption (CTC), patient-reported (PRO), and clinical outcomes in a longitudinal study of patients (pts) with breast cancer (BC) D Soldato, J Havas, D Presti, P Lapidari, N Rassy, B Pistilli, E Martin, ... Annals of Oncology 32, S1184, 2021 | 1 | 2021 |
